NCT07363343 Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study
| NCT ID | NCT07363343 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Cleveland Clinic |
| Condition | Hypertension |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2026-03-10 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2026-03-10 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.
Eligibility Criteria
Inclusion Criteria: * Postpartum women aged 18 years or older * Clinical diagnosis of hypertensive disorder in pregnancy (gestational hypertension, chronic hypertension, preeclampsia with or without severe features) * Taking Nifedipine 60 mg every 12 hours for blood pressure control * Persistently elevated blood pressure at/above 140/90 mmHg in a 24-hour time period or have one or more severe range blood pressure at/above 160/110 mmHg requiring a second antihypertensive medication * English speaking Exclusion Criteria: * Taking ≥2 antihypertensive agents during pregnancy * Heart block * Heart rate \<60 or \>120 beats per minute * Heart failure * Creatinine \>1.5 mg/dL * Renal artery stenosis * Active connective tissue disease * Cerebrovascular accident * Failed treatment or contraindications to nifedipine, enalapril or labetalol
Contact & Investigator
Amol Malshe, M.D.
PRINCIPAL INVESTIGATOR
The Cleveland Clinic
Frequently Asked Questions
Who can join the NCT07363343 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07363343 currently recruiting?
Yes, NCT07363343 is actively recruiting participants. Contact the research team at malshea@ccf.org for enrollment information.
Where is the NCT07363343 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT07363343 clinical trial?
NCT07363343 is sponsored by The Cleveland Clinic. The principal investigator is Amol Malshe, M.D. at The Cleveland Clinic. The trial plans to enroll 200 participants.